Share-based Payment Arrangement, Expense of Adaptimmune Therapeutics PLC from 30 Jun 2013 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Adaptimmune Therapeutics PLC quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2013 to 30 Jun 2025.
  • Adaptimmune Therapeutics PLC Share-based Payment Arrangement, Expense for the quarter ending 30 Jun 2025 was $1,321,000, a 57% decline year-over-year.
  • Adaptimmune Therapeutics PLC Share-based Payment Arrangement, Expense for the twelve months ending 30 Jun 2025 was $1,067,000, a 109% decline year-over-year.
  • Adaptimmune Therapeutics PLC annual Share-based Payment Arrangement, Expense for 2024 was $3,102,000, a 74% decline from 2023.
  • Adaptimmune Therapeutics PLC annual Share-based Payment Arrangement, Expense for 2023 was $11,773,000, a 35% decline from 2022.
  • Adaptimmune Therapeutics PLC annual Share-based Payment Arrangement, Expense for 2022 was $18,240,000, a 12% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Adaptimmune Therapeutics PLC Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $1,067,000 $1,321,000 -$1,736,000 -57% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $669,000 $669,000 -$2,433,000 -78% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $3,102,000 $6,111,000 -$9,188,000 -299% 01 Oct 2024 31 Dec 2024 10-Q 13 May 2025 2025 Q1
Q3 2024 $12,290,000 $3,054,000 -$129,000 -4.1% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2024 2024 Q3
Q2 2024 $12,419,000 $3,057,000 -$780,000 -20% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $13,199,000 $3,102,000 +$1,426,000 +85% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2024 2024 Q1
Q4 2023 $11,773,000 $3,077,000 -$869,000 -22% 01 Oct 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
Q3 2023 $12,642,000 $3,183,000 -$480,000 -13% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $13,122,000 $3,837,000 -$1,208,000 -24% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $14,330,000 $1,676,000 -$3,910,000 -70% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $18,240,000 $3,946,000 -$881,000 -18% 01 Oct 2022 31 Dec 2022 10-K 24 Mar 2025 2024 FY
Q3 2022 $19,121,000 $3,663,000 -$1,356,000 -27% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 $20,477,000 $5,045,000 -$404,000 -7.4% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $20,881,000 $5,586,000 +$252,000 +4.7% 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023 2023 Q1
Q4 2021 $20,629,000 $4,827,000 +$1,765,000 +58% 01 Oct 2021 31 Dec 2021 10-K 06 Mar 2024 2023 FY
Q3 2021 $18,864,000 $5,019,000 +$1,739,000 +53% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $17,125,000 $5,449,000 +$2,825,000 +108% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $14,300,000 $5,334,000 +$3,886,000 +268% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $10,414,000 $3,062,000 +$504,000 +20% 01 Oct 2020 31 Dec 2020 10-K 06 Mar 2023 2022 FY
Q3 2020 $9,910,000 $3,280,000 +$1,460,000 +80% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $8,450,000 $2,624,000 -$572,000 -18% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $9,022,000 $1,448,000 -$2,031,000 -58% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $11,053,000 $2,558,000 -$851,000 -25% 01 Oct 2019 31 Dec 2019 10-K 25 Feb 2021 2020 FY
Q3 2019 $11,904,000 $1,820,000 -$2,222,000 -55% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $14,126,000 $3,196,000 -$883,000 -22% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $15,009,000 $3,479,000 -$1,193,000 -26% 01 Jan 2019 31 Mar 2019 10-Q 14 May 2020 2020 Q1
Q4 2018 $16,202,000 $3,409,000 -$565,000 -14% 01 Oct 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
Q3 2018 $16,767,000 $4,042,000 +$1,970,000 +95% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019 2019 Q3
Q2 2018 $14,797,000 $4,079,000 +$2,007,000 +97% 01 Apr 2018 30 Jun 2018 10-Q 01 Aug 2019 2019 Q2
Q1 2018 $12,790,000 $4,672,000 +$1,986,000 +74% 01 Jan 2018 31 Mar 2018 10-Q 06 May 2019 2019 Q1
Q4 2017 $10,804,000 $3,974,000 +$1,952,000 +97% 01 Oct 2017 31 Dec 2017 10-K 27 Feb 2019 2018 FY
Q3 2017 $8,852,000 $2,072,000 -$214,000 -9.4% 01 Jul 2017 30 Sep 2017 10-Q 06 Nov 2018 2018 Q3
Q2 2017 $9,066,000 $2,072,000 -$367,000 -15% 01 Apr 2017 30 Jun 2017 10-Q 02 Aug 2018 2018 Q2
Q1 2017 $9,433,000 $2,686,000 +$612,000 +30% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
Q4 2016 $8,821,000 $2,022,000 01 Oct 2016 31 Dec 2016 10-K 27 Feb 2019 2018 FY
Q3 2016 $2,286,000 +$885,000 +63% 01 Jul 2016 30 Sep 2016 10-Q 02 Nov 2017 2017 Q3
Q2 2016 $2,439,000 -$2,371,000 -49% 01 Apr 2016 30 Jun 2016 10-Q 03 Aug 2017 2017 Q2
Q1 2016 $2,074,000 +$592,000 +40% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017 2017 Q1
Q3 2015 $1,401,000 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2016 2016 Q3
Q2 2015 $4,810,000 01 Apr 2015 30 Jun 2015 10-Q 08 Aug 2016 2016 Q2
Q1 2015 $1,482,000 01 Jan 2015 31 Mar 2015 10-Q 12 May 2016 2016 Q1

Adaptimmune Therapeutics PLC Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $3,102,000 -$8,671,000 -74% 01 Jan 2024 31 Dec 2024 10-Q 13 May 2025 2025 Q1
2023 $11,773,000 -$6,467,000 -35% 01 Jan 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
2022 $18,240,000 -$2,389,000 -12% 01 Jan 2022 31 Dec 2022 10-K 24 Mar 2025 2024 FY
2021 $20,629,000 +$10,215,000 +98% 01 Jan 2021 31 Dec 2021 10-K 06 Mar 2024 2023 FY
2020 $10,414,000 -$639,000 -5.8% 01 Jan 2020 31 Dec 2020 10-K 06 Mar 2023 2022 FY
2019 $11,053,000 -$5,149,000 -32% 01 Jan 2019 31 Dec 2019 10-K 25 Feb 2021 2020 FY
2018 $16,202,000 +$5,398,000 +50% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
2017 $10,804,000 +$1,983,000 +22% 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2019 2018 FY
2016 $8,821,000 +$1,743,000 +25% 01 Jan 2016 31 Dec 2016 10-K 27 Feb 2019 2018 FY
2015 $7,078,000 +$6,746,000 +2032% 01 Jul 2014 30 Jun 2015 10-K 15 Mar 2018 2017 FY
2014 $332,000 +$154,000 +87% 01 Jul 2013 30 Jun 2014 10-K 13 Mar 2017 2016 FY
2013 $178,000 01 Jul 2012 30 Jun 2013 8-K 08 Jul 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.